In August 2019, Botanix completed a A$40m US-led institutional placement. The funds from the
placement enables Botanix to execute its key clinical development programmes and accelerate its
broader commercialisation strategy. The Company is also expecting to receive approximately A$7m
in R&D tax incentive in 4Q CY2019. Botanix is now fully funded to progress the development of its
rosacea and antimicrobial programs into the clinic and undertake supportive studies required prior to
commencement of Phase 3 studies for BTX 1503.
Looking Forward to a GREAT 2020, page-8
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.005(1.52%) |
Mkt cap ! $527.6M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 34.5¢ | 33.0¢ | $1.170M | 3.464M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 308760 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 99273 | 7 |
View Market Depth
| Last trade - 13.02pm 18/06/2024 (20 minute delay) ? |
|
|||||
|
Last
34.0¢ |
Change
0.005 ( 1.31 %) |
||||
| Open | High | Low | Volume | ||
| 33.0¢ | 34.5¢ | 33.0¢ | 1436680 | ||
| Last updated 13.26pm 18/06/2024 ? | |||||
| BOT (ASX) Chart |